Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F2XQ
|
|||
| Former ID |
DAP000567
|
|||
| Drug Name |
Fludarabine
|
|||
| Synonyms |
FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Genzyme Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12FN5O4
|
|||
| Canonical SMILES |
C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
|
|||
| InChI |
1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
|
|||
| InChIKey |
HBUBKKRHXORPQB-FJFJXFQQSA-N
|
|||
| CAS Number |
CAS 21679-14-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855645, 7979234, 9268240, 12015425, 14751067, 15222429, 49865029, 53790210, 56310845, 57408458, 71840321, 74951141, 96024661, 99437182, 99453172, 103588722, 104170131, 113529123, 117527505, 118048763, 121362454, 123121326, 124757293, 124800219, 125164097, 128038069, 130399360, 131378849, 134994031, 135684141, 135697967, 135723536, 136342497, 136367939, 136375530, 137000684, 141858050, 144115985, 144206348, 144206969, 151994330, 152055900, 152344067, 162011966, 162036224, 163072527, 164216431, 166831392, 170464764, 172080756
|
|||
| ChEBI ID |
CHEBI:94701
|
|||
| ADReCS Drug ID | BADD_D00914 | |||
| SuperDrug ATC ID |
L01BB05
|
|||
| SuperDrug CAS ID |
cas=021679141
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Description | Fludarabine can be metabolized by Escherichia coli. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Fludarabine (adjusted p-values: 2.20E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine deaminase (ADA) | Target Info | Inhibitor | [5] |
| BioCyc | Purine nucleotides degradation | |||
| Purine deoxyribonucleosides degradation | ||||
| Purine ribonucleosides degradation to ribose-1-phosphate | ||||
| Adenosine nucleotides degradation | ||||
| Superpathway of purine nucleotide salvage | ||||
| Adenine and adenosine salvage III | ||||
| KEGG Pathway | Purine metabolism | |||
| Metabolic pathways | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| C-MYB transcription factor network | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Purine salvage | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017 Jun 23;356(6344):eaag2770. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.